This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street

Moderna shares have surged more than 560% this year, giving the company a $77 billion market capitalization, while its average analyst price target of $121 implies 38% downside. The article cites approval of its mRNA flu vaccine and positive Phase 3 results for its personalized melanoma cancer vaccine as pipeline advances, but notes Q2 revenue was $145 million and the company remained unprofitable; the author considers the valuation difficult to justify and recommends waiting for a dip.

Analysis

The key valuation risk is a gap between clinical proof-of-concept and cash-flow conversion. For Moderna, the flu opportunity depends not just on efficacy but on manufacturing readiness, strain-selection timing, regulator release schedules, uptake, and displacement of established products from Sanofi and GSK. Faster design alone does not guarantee a better-matched vaccine reaches patients in time. Watch launch orders and market share, not the addressable-market estimate.

The melanoma result improves the probability that Moderna has value beyond respiratory vaccines, but it does not yet establish broad oncology economics. Recurrence-free survival must translate into regulatory acceptance, durable benefit, and use at scale; the multiple other cancer programs remain separate clinical risks. Merck may benefit through incremental Keytruda use or duration, but the size and division of economics with Moderna are not established by the article.

Near term, a sharp re-rating can persist while investors price pipeline optionality; analyst targets are not a catalyst by themselves. Over 1–3 months, launch evidence, full trial details, and guidance are more useful tests. Over 6–18 months, commercial uptake and additional readouts determine whether pipeline value converts into cash flow. The contrarian risk to the bearish valuation view is that successful oncology data can support a platform premium before revenues arrive. Conversely, failure to show commercial traction or confirmatory benefit would expose the thin current revenue base to multiple compression.

Key Decisions for Investors

• Do not initiate a momentum-driven MRNA position on the headline alone. For existing holders, consider staged profit-taking rather than an all-or-nothing exit; re-entry is more defensible after a pullback or evidence of commercial conversion.
• Treat any bearish MRNA trade as conditional, not as a valuation-target trade: consider defined-risk downside exposure only if the post-news price remains extended and option pricing is reasonable. Avoid naked shorting given the risk of further oncology-driven repricing.
• Track mFLUSIVA launch orders, share gains versus Sanofi and GSK, and any evidence that strain selection and production timing work in practice. Weak uptake or execution slippage would falsify the near-term commercial thesis.
• For the cancer-vaccine thesis, verify the complete Phase 3 dataset, regulatory pathway, overall-survival follow-up, and disclosed commercial economics with Merck. Failure to confirm durable clinical benefit would undermine the platform-premium case; stronger evidence could invalidate a near-term bearish stance.